155229-75-7

Basic information

• Product Name: (+)-3R,5S-FLUVASTATIN SODIUM SALT
• Synonyms: (+)-3R,5S-FLUVASTATIN SODIUM SALT;(3R,5S,6E)-7-[3-(4-Fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid;(+)-3R,5S-Fluvastatin-d6 sodiuM salt
• CAS NO: 155229-75-7
• Molecular Formula: C24H25FNNaO4
• Molecular Weight: 433.45
• Mol File: 155229-75-7.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 681.8 °C at 760 mmHg
• Flash Point: 366.1 °C
• Appearance: /
• Density: 1.23
• Storage Temp.: -20°C Freezer
• Solubility: DMSO, Methanol, Water
• PKA: 4.27±0.10(Predicted)
• CAS DataBase Reference: (+)-3R,5S-FLUVASTATIN SODIUM SALT(CAS DataBase Reference)
• NIST Chemistry Reference: (+)-3R,5S-FLUVASTATIN SODIUM SALT(155229-75-7)
• EPA Substance Registry System: (+)-3R,5S-FLUVASTATIN SODIUM SALT(155229-75-7)

Safety Data

• Hazardous Substances Data: 155229-75-7(Hazardous Substances Data)

Usage

Uses

A synthetic HMG-CoA reductase inhibitor. Antilipemic.This compound contains residual sodium chloride which is quantified on the certificate of analysis.

Upstream product

• 129332-29-2 R*,S*-(E)-(+/-)-3,5-dihydroxy-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-6-heptenoic acid tert-butyl ester 
• 94061-80-0 fluvastatin sodium 

Downstream Products

• 1352078-35-3 C₂₄H₂₆FNO₃ 

Relevant articles and documents

Multi-substituted indoles lactone dehydration compound and use thereof

The invention provides a compound, belonging to the field of medicinal chemistry. A structural formula of the compound is described in the specification. According to a test, the compound has the effects of restraining the activity of HMG-coA reductase, and can be used as a new-generation potential HMG-coA reductase inhibitor.

SUBSTANTIALLY PURE AMORPHOUS FLUVASTATIN, PROCESSES FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME

A process for producing fluvastatin or a pharmaceutically acceptable salt thereof in a substantially pure amorphous form is provided comprising (a) providing a solvent solution comprising substantially non-amorphous fluvastatin or a pharmaceutically accep

Treatment of type 1 diabetes with PDE5 inhibitors

The use of a PDE5 inhibitor without substantial PDE2 inhibiting activity, or a pharmaceutically acceptable salt thereof in the preparation of a medicament for the treatment of Type 1 Diabetes. A method of treating Type 1 Diabetes in an individual suffering from Type 1 Diabetes, which method comprises administering to said individual an effective amount of a PDE5 inhibitor without substantial PDE2 inhibiting activity, or a pharmaceutically acceptable salt thereof.